AIO-Studien-gGmbH

Oncolytics Biotech's Pelareorep Advances in Pancreatic Cancer Trial with Regulatory Approval

4 months ago

• The Paul-Ehrlich-Institute (PEI) in Germany has approved the continuation of patient enrollment into Cohort 5 of the GOBLET study. • Cohort 5 is evaluating pelareorep in combination with mFOLFIRINOX with or without atezolizumab in newly diagnosed PDAC patients. • Early safety data will be presented at the upcoming ASCO Gastrointestinal Cancers Symposium, with initial efficacy results expected in the second half of the year.

Oncolytics' Pelareorep Shows Promise in Pancreatic Cancer Trial, GOBLET Cohort 5 Enrollment Continues

6 months ago

• The Data Safety Monitoring Board (DSMB) has recommended continued enrollment in Cohort 5 of the GOBLET study, which is evaluating pelareorep in pancreatic cancer. • Cohort 5 is assessing pelareorep combined with mFOLFIRINOX, with or without atezolizumab, in patients with newly diagnosed pancreatic ductal adenocarcinoma (PDAC). • Initial safety data from the trial's safety run-in phase support the continued evaluation of pelareorep in combination with chemotherapy and immunotherapy. • Updates from the trial, including safety and efficacy data, are expected in 2025, offering potential advancements in PDAC treatment.

Oncolytics Biotech and Bio-Path Holdings Announce Promising Cancer Therapy Advancements

6 months ago

• Oncolytics Biotech presented data at the ASCO GI Symposium, highlighting pelareorep's potential in treating relapsed anal and metastatic pancreatic cancers. • A GOBLET study cohort showed a 33% objective response rate in relapsed anal cancer patients treated with pelareorep and atezolizumab, including a complete response lasting over 15 months. • Bio-Path Holdings reported a meaningful patient response in a Phase 1/1b trial of BP1002 for refractory/relapsed AML, with stable disease and reduced blast count after one treatment cycle. • Bio-Path Holdings' BP1001-A demonstrated continued tumor reduction and stable disease in a solid tumor patient, alongside durable remissions in AML patients treated with prexigebersen.